{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:58:10Z","timestamp":1785466690887,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05780-1","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:59:02Z","timestamp":1785463142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The real-world safety of ruxolitinib in graft-versus-host disease treatment: a pharmacovigilance study based on the FDA adverse event reporting system"],"prefix":"10.1007","author":[{"given":"Yuan-yuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-long","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng-zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-ji","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"5780_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720914489","volume":"11","author":"R Abboud","year":"2020","unstructured":"Abboud R, Choi J, Ruminski P, Schroeder MA, Kim S, Abboud CN, DiPersio JF (2020) Insights into the role of the JAK\/STAT signaling pathway in graft-versus-host disease. Ther Adv Hematol 11:2040620720914489. https:\/\/doi.org\/10.1177\/2040620720914489","journal-title":"Ther Adv Hematol"},{"key":"5780_CR2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00280-019-03907-1","volume":"84","author":"V Aslanis","year":"2019","unstructured":"Aslanis V, Umehara K, Huth F, Ouatas T, Bharathy S, Butler AA, Zhou W, Gadbaw B (2019) Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects. Cancer Chemother Pharmacol 84:749\u201357. https:\/\/doi.org\/10.1007\/s00280-019-03907-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"5780_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2022.12.024","volume":"90","author":"E Baumrin","year":"2024","unstructured":"Baumrin E, Loren AW, Falk SJ, Mays JW, Cowen EW (2024) Chronic graft-versus-host disease. Part I: epidemiology, pathogenesis, and clinical manifestations. J Am Acad Dermatol 90:1\u201316. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.024","journal-title":"J Am Acad Dermatol"},{"key":"5780_CR4","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1093\/ejendo\/lvaf182","volume":"193","author":"T Diker Cohen","year":"2025","unstructured":"Diker Cohen T, Dotan I, Calvarysky B, Robenshtok E (2025) Endocrine effects of long-term calcineurin inhibitor use in solid organ transplant recipients. Eur J Endocrinol 193:R1\u2013R16. https:\/\/doi.org\/10.1093\/ejendo\/lvaf182","journal-title":"Eur J Endocrinol"},{"key":"5780_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954268","volume":"13","author":"S Fan","year":"2022","unstructured":"Fan S, Huo WX, Yang Y, Shen MZ, Mo XD (2022) Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: a meta-analysis. Front Immunol 13:954268. https:\/\/doi.org\/10.3389\/fimmu.2022.954268","journal-title":"Front Immunol"},{"key":"5780_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.14740\/jh642","volume":"9","author":"F Furia","year":"2020","unstructured":"Furia F, Canevini MP, Federici AB, Carraro MC (2020) Unexpected neurological symptoms of ruxolitinib: a case report. J Hematol 9:137\u2013139. https:\/\/doi.org\/10.14740\/jh642","journal-title":"J Hematol"},{"key":"5780_CR7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/2040620713489842","volume":"4","author":"C Garnett","year":"2013","unstructured":"Garnett C, Apperley JF, Pavlu J (2013) Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol 4:366\u2013378. https:\/\/doi.org\/10.1177\/2040620713489842","journal-title":"Ther Adv Hematol"},{"key":"5780_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020224","author":"A Gonneaud","year":"2021","unstructured":"Gonneaud A, Turgeon N, Boisvert FM, Boudreau F, Asselin C (2021) JAK-STAT pathway inhibition partially restores intestinal homeostasis in Hdac1- and Hdac2-intestinal epithelial cell-deficient mice. Cells. https:\/\/doi.org\/10.3390\/cells10020224","journal-title":"Cells"},{"key":"5780_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.25376","volume":"94","author":"M Gonzalez Vicent","year":"2019","unstructured":"Gonzalez Vicent M, Molina B, Gonzalez de Pablo J, Castillo A, Diaz MA (2019) Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: clinical and immunological results. Am J Hematol 94:319\u2013326. https:\/\/doi.org\/10.1002\/ajh.25376","journal-title":"Am J Hematol"},{"key":"5780_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/nu14173660","author":"KM Hsu","year":"2022","unstructured":"Hsu KM, Lin PR, Chiu PF, Hsieh YP (2022) Infection in living donor liver transplantation leads to increased risk of adverse renal outcomes. Nutrients. https:\/\/doi.org\/10.3390\/nu14173660","journal-title":"Nutrients"},{"key":"5780_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","volume":"119","author":"M Jagasia","year":"2012","unstructured":"Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T (2012) Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 119:296\u2013307. https:\/\/doi.org\/10.1182\/blood-2011-06-364265","journal-title":"Blood"},{"key":"5780_CR12","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood.2020004823","volume":"135","author":"M Jagasia","year":"2020","unstructured":"Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ (2020) Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood 135:1739\u20131749. https:\/\/doi.org\/10.1182\/blood.2020004823","journal-title":"Blood"},{"key":"5780_CR13","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood.2023021046","volume":"143","author":"C Keenan","year":"2024","unstructured":"Keenan C, Albeituni S, Oak N, Stroh A, Tillman HS, Wang Y, Freeman BB 3rd, Aleman-Arteaga S, Meyer LK, Woods R, Verbist KC, Zhou Y, Cheng C, Nichols KE (2024) Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis. Blood 143:2386\u2013400. https:\/\/doi.org\/10.1182\/blood.2023021046","journal-title":"Blood"},{"key":"5780_CR14","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/ibd\/izad007","volume":"29","author":"C Li","year":"2023","unstructured":"Li C, Xu Y, Gao T, Zhang S, Lin Z, Gu S, Fang Y, Yuan X, Yu S, Jiang Q, Lou Z, Zhang X, Zhang J, Wu Q, Gu M, Ding X, Sun J, Chen Y (2023) Ruxolitinib alleviates inflammation, apoptosis, and intestinal barrier leakage in ulcerative colitis via STAT3. Inflamm Bowel Dis 29:1191\u20131201. https:\/\/doi.org\/10.1093\/ibd\/izad007","journal-title":"Inflamm Bowel Dis"},{"key":"5780_CR15","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/blood.2023022565","volume":"144","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Kang HJ, Bruno B, Gandemer V, Rialland F, Faraci M, Takahashi Y, Koh K, Bittencourt H, Cleary G, Rosko C, Li X, St Pierre A, Prahallad A, Diaz-de-Heredia C (2024) Ruxolitinib for pediatric patients with treatment-naive and steroid-refractory acute graft-versus-host disease: the REACH4 study. Blood 144:2095\u2013106. https:\/\/doi.org\/10.1182\/blood.2023022565","journal-title":"Blood"},{"key":"5780_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ajh.24976","volume":"93","author":"F Lussana","year":"2018","unstructured":"Lussana F, Cattaneo M, Rambaldi A, Squizzato A (2018) Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol 93:339\u201347. https:\/\/doi.org\/10.1002\/ajh.24976","journal-title":"Am J Hematol"},{"key":"5780_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.36290\/vnl.2022.041","volume":"68","author":"Z Lys","year":"2022","unstructured":"Lys Z, Dombrovska K, Dedochova J, Kovarova P, Valkovsky I, Vaclavik J (2022) Acute infections in kidney transplant recipients. Vnitr Lek 68:12\u201317","journal-title":"Vnitr Lek"},{"key":"5780_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176403","volume":"968","author":"J Min","year":"2024","unstructured":"Min J, Zheng H, Xia H, Tian X, Liang M, Zhang J, Huang W (2024) Ruxolitinib attenuates microglial inflammatory response by inhibiting NF-kappaB\/MAPK signaling pathway. Eur J Pharmacol 968:176403. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176403","journal-title":"Eur J Pharmacol"},{"key":"5780_CR19","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO-25-00809","volume":"43","author":"M Mohty","year":"2025","unstructured":"Mohty M, Socie G, Szer J, Niederwieser D, Butler J, Wagner-Drouet E, Or R, Rovenvald-Zuckerman T, Bozdag SC, Forcade E, Grillo G, Kroger N, Stolzel F, Russo D, Sanz J, Sarkar R, Stefanelli T, Wilke C, Zeiser R, von Bubnoff N (2025) Ruxolitinib versus best available therapy in patients with steroid-refractory acute graft-versus-host disease: final analysis from the randomized phase III REACH2 trial. J Clin Oncol 43:3639\u201345. https:\/\/doi.org\/10.1200\/JCO-25-00809","journal-title":"J Clin Oncol"},{"key":"5780_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1033490","volume":"13","author":"L Neidemire-Colley","year":"2022","unstructured":"Neidemire-Colley L, Robert J, Ackaoui A, Dorrance AM, Guimond M, Ranganathan P (2022) Role of endothelial cells in graft-versus-host disease. Front Immunol 13:1033490. https:\/\/doi.org\/10.3389\/fimmu.2022.1033490","journal-title":"Front Immunol"},{"key":"5780_CR21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s12185-024-03850-9","volume":"120","author":"S Shiratori","year":"2024","unstructured":"Shiratori S, Fukushima K, Onishi Y, Doki N, Goto T, Okada M, Nakamae H, Maeda Y, Kato K, Ishikawa T, Kondo T, Toyosaki M, Ikeda T, Uchida N, Maki A, Shimada F, Tajima T, Stefanelli T, Teshima T (2024) Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study. Int J Hematol 120:705\u2013716. https:\/\/doi.org\/10.1007\/s12185-024-03850-9","journal-title":"Int J Hematol"},{"key":"5780_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13071044","author":"P Smith","year":"2021","unstructured":"Smith P, Yao W, Shepard S, Covington M, Lee J, Lofland J, Naim A, Sheth T, Parikh B, Yeleswaram S (2021) Developing a JAK inhibitor for targeted local delivery: ruxolitinib cream. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics13071044","journal-title":"Pharmaceutics"},{"key":"5780_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/imr.12705","volume":"286","author":"H Stabile","year":"2018","unstructured":"Stabile H, Scarno G, Fionda C, Gismondi A, Santoni A, Gadina M, Sciume G (2018) JAK\/STAT signaling in regulation of innate lymphoid cells: the gods before the guardians. Immunol Rev 286:148\u201359. https:\/\/doi.org\/10.1111\/imr.12705","journal-title":"Immunol Rev"},{"key":"5780_CR24","doi-asserted-by":"publisher","first-page":"E181","DOI":"10.1002\/ajh.25804","volume":"95","author":"S Strohbehn","year":"2020","unstructured":"Strohbehn S, Seethapathy H, Rusibamayila N, Strohbehn I, Lee M, Hobbs G, Keyzner A, Jhaveri KD, Sise ME (2020) Acute kidney injury after ruxolitinib: common complication, uncommon cause. Am J Hematol 95:E181\u2013E83. https:\/\/doi.org\/10.1002\/ajh.25804","journal-title":"Am J Hematol"},{"key":"5780_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2026.2634532","volume":"58","author":"S Tan","year":"2026","unstructured":"Tan S, Li Y, Cao Y, Sun W, Hui W (2026) Efficacy and safety of Ruxolitinib-based combination therapy in the patients with myelofibrosis (MF): a systematic review and meta-analysis. Ann Med 58:2634532. https:\/\/doi.org\/10.1080\/07853890.2026.2634532","journal-title":"Ann Med"},{"key":"5780_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137109","author":"Z Tothova","year":"2021","unstructured":"Tothova Z, Tomc J, Debeljak N, Solar P (2021) STAT5 as a key protein of erythropoietin signalization. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22137109","journal-title":"Int J Mol Sci"},{"key":"5780_CR27","doi-asserted-by":"publisher","DOI":"10.1515\/dmpt-2018-0042","author":"K Umehara","year":"2019","unstructured":"Umehara K, Huth F, Jin Y, Schiller H, Aslanis V, Heimbach T, He H (2019) Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. Drug Metab Pers Ther. https:\/\/doi.org\/10.1515\/dmpt-2018-0042","journal-title":"Drug Metab Pers Ther"},{"key":"5780_CR28","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr., Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"key":"5780_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr., Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H, Comfort- I. investigators (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10:55. https:\/\/doi.org\/10.1186\/s13045-017-0417-z","journal-title":"J Hematol Oncol"},{"key":"5780_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.748019","volume":"12","author":"JM Vinnakota","year":"2021","unstructured":"Vinnakota JM, Zeiser R (2021) Acute graft-versus-host disease, infections, vascular events and drug toxicities affecting the central nervous system. Front Immunol 12:748019. https:\/\/doi.org\/10.3389\/fimmu.2021.748019","journal-title":"Front Immunol"},{"key":"5780_CR31","doi-asserted-by":"publisher","first-page":"1680188","DOI":"10.3389\/fmed.2025.1680188","volume":"12","author":"C Xie","year":"2025","unstructured":"Xie C, Shi L, Wei Z, Lai Y, Liu R (2025) Efficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Front Med (Lausanne) 12:1680188. https:\/\/doi.org\/10.3389\/fmed.2025.1680188","journal-title":"Front Med (Lausanne)"},{"key":"5780_CR32","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/DDDT.S287218","volume":"15","author":"W Yang","year":"2021","unstructured":"Yang W, Zhu G, Qin M, Li Z, Wang B, Yang J, Wang T (2021) The effectiveness of ruxolitinib for acute\/chronic graft-versus-host disease in children: a retrospective study. Drug des Devel Ther 15:743\u2013752. https:\/\/doi.org\/10.2147\/DDDT.S287218","journal-title":"Drug des Devel Ther"},{"key":"5780_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1621708","volume":"16","author":"Y Yang","year":"2025","unstructured":"Yang Y, Huo Y, Zhou D, Kang Z, Huang Y, Wang Y, Fan G, Ma L, Yan J (2025) Efficacy and safety of ruxolitinib combined with steroids for first-line treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: a single-center, real-world experience. Front Immunol 16:1621708. https:\/\/doi.org\/10.3389\/fimmu.2025.1621708","journal-title":"Front Immunol"},{"key":"5780_CR34","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR (2017) Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med 377:2167\u201379. https:\/\/doi.org\/10.1056\/NEJMra1609337","journal-title":"N Engl J Med"},{"key":"5780_CR35","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socie G, Reach Trial Group (2020) Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med 382:1800\u201310. https:\/\/doi.org\/10.1056\/NEJMoa1917635","journal-title":"N Engl J Med"},{"key":"5780_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F, Reach Investigators (2021) Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med 385:228\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2033122","journal-title":"N Engl J Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05780-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05780-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05780-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:59:03Z","timestamp":1785463143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05780-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":36,"alternative-id":["5780"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05780-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"31 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required for the study involving humans in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was not required from the participants or the participants\u2019 legal guardians\/next of kin in accordance with the national legislation and the institutional requirements.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors utilized DeepSeek (\n                      \n                      ) for grammatical improvements in this manuscript. The authors take full responsibility for the content of the publication.","order":3,"name":"Ethics","label":"Generative AI statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}